Trial Profile

An open-label extension, multi-center, study to evaluate the safety of SD-101 cream in subjects with epidermolysis bullosa

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allantoin (Primary)
Indications Epidermolysis bullosa
Focus Adverse reactions
Sponsors Scioderm

Most Recent Events

12 Nov 2018 Status changed from active, no longer recruiting to discontinued.
10 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
10 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com